InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Clearance for Depression and Suicidality Trial
May 7, 2026
NRx Pharmaceuticals (NASDAQ: NRXP) announced that the U.S. Food and Drug Administration cleared the company to initiate a Phase 2/3 clinical trial evaluating NRX-101 in patients with treatment-resistant major depressive disorder and suicidality receiving active or sham transcranial magnetic stimulation, with the study to be conducted by subsidiary NRx Defense Systems and expected to enroll 240 […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Initiates First Commercial Manufacturing Order For Preservative-Free Ketamine
May 5, 2026
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has initiated its first commercial manufacturing order of preservative-free ketamine in anticipation of potential approval under the Generic Drug User Fee Act in summer 2026, supported by stability data from multiple registration batches and a successful third-party manufacturing audit. To view the full press release, visit https://ibn.fm/yEXl3 About NRx […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress
April 22, 2026
NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a positive Discipline Review Letter from the FDA Office of Generic Drugs covering quality-related aspects of its ketamine ANDA, with only minor administrative updates requested. The company also reported a supportive meeting with FDA leadership aligned with federal priorities to accelerate treatments for severe mental illness, reinforcing expectations for […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development
April 20, 2026
NRx Pharmaceuticals (NASDAQ: NRXP) welcomed a newly signed Executive Order aimed at accelerating medical treatments for serious mental illness, including expanded access to psychedelic therapies and faster regulatory pathways. The order directs the FDA to issue priority vouchers for qualifying breakthrough therapies and encourages broader use of clinical trial data and real-world evidence, aligning with NRx’s […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications
April 15, 2026
NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems Inc., a Florida-based research and development subsidiary dedicated to advancing combined neuroplastic treatments using D-cycloserine and transcranial magnetic stimulation supported by robotic-enabled neuronavigation. The subsidiary will be led by Dr. Dennis McBride, with […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints First Chief Commercial Officer Ahead of Ketamine Launch
April 13, 2026
NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression, PTSD and related conditions, announced the appointment of Glenn Tyson as its first Chief Commercial Officer as the company prepares for anticipated approval of its Abbreviated New Drug Application for a preservative-free ketamine product. Tyson brings more than 25 years of commercialization and sales experience, […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Labeling Feedback for Preservative-Free Ketamine Application
April 6, 2026
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has received a letter from the FDA Office of Generic Drugs indicating only minor formatting comments on the proposed label for its preservative-free ketamine product, with a final label submission expected this month and potential approval of its Abbreviated New Drug Application anticipated in Summer 2026 pending final review. […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress
March 24, 2026
NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec. 31, 2025, highlighting progress across its clinical-stage pipeline and HOPE Therapeutics operations, including advancing two drug candidates toward FDA approval and opening its first HOPE Therapeutics clinics focused on neuroplastic care. The company reported a reduced operating loss of $16.2 […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules March 24 Conference Call To Review 2025 Results And Clinical Progress
March 19, 2026
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will host a conference call at 8:00 a.m. ET on March 24, 2026, to review financial results for the fiscal year ended Dec. 31, 2025, and provide updates on progress across its drug development programs and the HOPE Therapeutics clinical network, highlighting milestones aligned with its […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product
March 17, 2026
NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a letter from the FDA’s Bioequivalence Program stating no bioequivalence deficiencies were identified at this time in its Abbreviated New Drug Application, with a preliminary determination ahead of anticipated approval in Summer 2026. The company highlighted its preservative-free ketamine formulation, which excludes benzethonium chloride, as a potential advancement in safety and stability, while continuing to pursue […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Guidance Supporting NDA Review For NRX-100
March 16, 2026
NRx Pharmaceuticals (NASDAQ: NRXP) announced that minutes from a Type C meeting with the U.S. Food and Drug Administration support the agency’s willingness to review a New Drug Application for NRX-100, a preservative-free ketamine formulation, based on existing clinical trial data demonstrating substantial evidence of effectiveness without requiring additional clinical trials. The company said the […]
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Appoints TMS, Neuroplasticity Researcher Joshua Brown MD, PhD, as Chief Medical Innovation Officer
March 11, 2026
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has appointed neurostimulation researcher Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer, bringing a prominent academic voice in brain stimulation therapies into its leadership ranks (https://ibn.fm/zaQzM). The company is developing treatments targeting central nervous system disorders including suicidal depression and Post-Traumatic Stress Disorder (“PTSD”). […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Opens Palm Beach Clinic for Depression and PTSD Treatment
March 9, 2026
NRx Pharmaceuticals (NASDAQ: NRXP) announced that its subsidiary HOPE Therapeutics has opened a new clinic in Palm Beach, Florida, focused on treating depression and post-traumatic stress disorder through an interventional psychiatry approach that includes ketamine and other neuroplastic drugs, transcranial magnetic stimulation (TMS), hyperbaric oxygen therapy and physician-led psychotherapy. The facility expands HOPE’s growing network […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer
March 2, 2026
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has appointed Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer. Prof. Brown is a psychiatrist, neurologist and neuroscientist who studies the mechanisms of Transcranial Magnetic Stimulation (TMS) and their translation into clinical optimization. He serves as Medical Director of the McLean Hospital TMS Service, […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway
February 17, 2026
NRx Pharmaceuticals (NASDAQ: NRXP) announced completion of an in-person Type C guidance meeting with the U.S. Food and Drug Administration, attended by leadership from the Division of Psychiatry Products, Office of Neuroscience and Center for Drug Evaluation and Research. Based on oral guidance, the company believes it has a path to file a New Drug Application […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100
January 14, 2026
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has licensed regulatory-grade real-world evidence drawn from more than 70,000 U.S. patients treated with intravenous ketamine or nasal S-ketamine for depression and suicidal ideation to support its application for Accelerated Approval of NRX-100, a preservative-free ketamine, under Fast Track Designation. The dataset, provided by Osmind, includes nearly one million […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Partners With neurocare Group AG To Build Nationwide Neuroplastic Care Network
January 5, 2026
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced a partnership with neurocare Group AG to create a nationwide network of clinics offering integrated neuroplastic care for depression, PTSD, and other serious mental health disorders. The planned model combines transcranial magnetic stimulation with ketamine and other neuroplastic drugs, hyperbaric oxygen therapy, and supportive psychotherapy, building on pilot programs that demonstrated high […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion
December 18, 2025
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has repaid the remaining $5.4 million of balance sheet debt owed to Anson Funds LLC through an equity conversion into common stock with no warrants or repricing mechanisms, fully retiring the original $16.2 million loan used for prior debt repayment and operating expenses. With the transaction completed, the clinical-stage […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment
December 3, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug filing for NRX-101 to include use of the drug in combination with Transcranial Magnetic Stimulation for depression, including suicidal depression. The update follows evidence suggesting NRX-101 may significantly enhance TMS outcomes, with published studies showing more than two-fold improvements in […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date
December 2, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated New Drug Application for KETAFREE(TM), a preservative-free intravenous ketamine formulation, deeming the submission “substantially complete” and assigning a July 29, 2026 review goal date. CEO Jonathan Javitt said KETAFREE is designed to provide a single-patient, preservative-free alternative to current multidose […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules Corporate Update Call for Dec. 2
December 2, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it will host a corporate update conference call on Dec. 2, 2025, at 9 a.m. Eastern to review recent clinical, regulatory and operational developments. To view the full press release, visit https://ibn.fm/eddP5 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at NobleCon21
December 1, 2025
NRx Pharmaceuticals (NASDAQ: NRXP) said Founder, Chairman and CEO Jonathan Javitt, M.D., M.P.H., will present at NobleCon21 on Dec. 3 at 4:30 p.m. EST, offering an update on the company’s expanded focus in investigational drugs, medical devices, and interventional psychiatric therapies for suicidal depression, PTSD, and related conditions, as well as progress in generating clinical […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs
November 17, 2025
NRx Pharmaceuticals (NASDAQ: NRXP) reported third-quarter 2025 results and outlined progress across its clinical programs, noting its first revenue-generating activities and key regulatory milestones for NRX-100 and NRX-101. The Company highlighted expanded Fast Track status and an active Expanded Access program for NRX-100 in suicidal depression, continued advancement of its NDA supported by large-scale real-world […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17
November 12, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will release its third quarter 2025 financial results before market open on Monday, Nov. 17, 2025, followed by a conference call at 8:30 a.m. ET to discuss corporate, financial, and operational updates. To view the full press release, visit https://ibn.fm/xcUKb About NRx Pharmaceuticals, Inc. NRx […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida
November 10, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), announced that its subsidiary, HOPE Therapeutics(TM), has initiated patient care using the Ampa “one day” (ONE-D) protocol for treatment-resistant depression—the first deployment of its kind in Florida and among the first nationwide. The Ampa device combines a single day of transcranial magnetic stimulation (TMS) with physician-prescribed D-cycloserine and lisdexamfetamine, which in […]
InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market
October 24, 2025
NRx Pharmaceuticals (NASDAQ: NRXP) was featured in a recent article that discussed its approach to bring preservative-free ketamine-based therapies to market, pursuing distinct regulatory and commercial pathways for both KETAFREE(TM) and NRX-100. “The company recently refiled an Abbreviated New Drug Application (‘ANDA’) for KETAFREE(TM), a preservative-free intravenous (‘IV’) ketamine formulation intended for all currently approved […]
InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advances KETAFREE(TM), Expands Pipeline Targeting Urgent Needs
October 16, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, recently secured approval from the U.S. Food and Drug Administration (“FDA”) for its Suitability Petition to advance KETAFREE(TM), a preservative-free version of ketamine. “The ruling allows the company to re-file its Abbreviated New Drug Application (‘ANDA’) for the product, which it has now done, a key step […]
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies
October 16, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, is advancing a two-pronged approach to bring preservative-free ketamine-based therapies to market, pursuing distinct regulatory and commercial pathways for both KETAFREE(TM) and NRX-100. (https://ibn.fm/BYg97). The company recently refiled an Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free intravenous (“IV”) ketamine formulation intended for all currently approved […]
InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based Therapies
October 8, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has re-filed an Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free intravenous (“IV”) ketamine formulation intended for all currently approved ketamine indications. This follows FDA approval of NRx’s Suitability Petition… KETAFREE(TM) is designed to eliminate benzethonium chloride (“BZT”), a known neurotoxic and cytotoxic preservative still present […]
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition
October 7, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it has received approval from the U.S. Food and Drug Administration (“FDA”) for its Suitability Petition to advance KETAFREE(TM), a preservative-free version of ketamine (https://ibn.fm/qFzsh). The ruling allows the company to re-file its Abbreviated New Drug Application (“ANDA”) for the product, which it has now done, […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
October 6, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly owned subsidiary HOPE Therapeutics Inc., announced that Founder, Chairman, and CEO Dr. Jonathan Javitt will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on Oct. 8, 2025, at 9:30 a.m. ET. Dr. Javitt will discuss the upcoming launch of a low-dose […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)
September 29, 2025
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has re-filed its Abbreviated New Drug Application with the U.S. FDA for KETAFREE(TM), a preservative-free IV ketamine formulation, covering all existing approved indications, following FDA approval of its Suitability Petition. Targeting a ketamine market estimated at $750 million annually in the U.S. and projected to reach $3.35 billion globally […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product
September 24, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted its Suitability Petition for KETAFREE(TM), a planned single-patient, preservative-free ketamine product. Unlike current ketamine offerings in multi-dose vials containing the toxic preservative Benzethonium Chloride, KETAFREE(TM) is designed to eliminate such additives. The approval enables immediate re-filing of […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical
September 8, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that its wholly owned subsidiary HOPE Therapeutics Inc. has closed the acquisition of Dura Medical, a revenue-generating and EBITDA-positive provider of interventional psychiatry services in Naples and Ft. Myers, Florida. Dura, founded in 2018, delivers treatments for depression, PTSD, suicidality, anxiety, and chronic pain through Ketamine […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join H.C. Wainwright’s 27th Annual Global Investment Conference; CEO Fireside Chat Set for Sept. 8, 2025, 4:30 to 5 p.m. ET
September 3, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc. (“HOPE”), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, announced that Chairman and CEO Jonathan Javitt, M.D., M.P.H., will participate in a fireside chat at H.C. Wainwright’s 27th Annual Global Investment Conference on Monday, Sept. 8, 2025, from 4:30 to 5 p.m. […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Showcases HOPE Therapeutics at Global Passion Project Event
September 2, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks at the Global Passion Project and Rockefeller Capital symposium held Aug. 28–30, 2025, in Southampton, N.Y. CEO Prof. Jonathan Javitt, MD, MPH, outlined plans for the Fall 2025 launch of HOPE Therapeutics clinics and a one-week residential program targeting suicidal depression, PTSD, traumatic […]
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression
September 2, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its intravenous ketamine formulation, NRX-100, for the treatment of suicidal ideation in patients with depression, including bipolar depression (https://nnw.fm/Y6Dpt) (https://ibn.fm/LYPf7). The new designation expands NRX-100’s potential patient population by tenfold compared to […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation
August 27, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced its expanded access policy for NRX-100 (preservative-free ketamine) after receiving FDA Fast Track designation for the treatment of suicidal ideation in patients with depression, including bipolar depression. The designation reflects FDA’s determination that NRX-100 may address an unmet need based on preliminary data. Eligible patients may […]
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
August 22, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has submitted a formal Citizen Petition to the U.S. Food and Drug Administration (“FDA”), urging the agency to prohibit the use of benzethonium chloride in all ketamine products sold in the United States. According to the company, this chemical preservative presents known toxicity risks and is not […]
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment
August 18, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, reported financial results for the quarter ended June 30, 2025, and provided a corporate update. The Company highlighted progress in all three lead programs, including expanded FDA Fast Track designation for NRX-100 in treating suicidal depression, filing of multiple regulatory documents, and advancement of the NRX-101 NDA. […]